Biomarker Testing Journey Among Patients with Advanced Solid Tumors and Treatment Patterns by Homologous Recombination Repair Status: A Clinico-Genomic Database Study.

Changxia ShaoYixin RenHeng ZhouLiam C LeeCai ChenElisha J DettmanRazvan CristescuAlexander GozmanFan JinWei Zhou

Published in: Advances in therapy (2024)

CDx testing after initiation of first-line treatment. Testing appeared to influence treatment patterns, with a higher proportion of patients with BRCAm, HRRm, and HRD-positive disease receiving PARP inhibitors.

Keyphrases

dna damage
dna repair
gene expression
combination therapy
adverse drug
genome wide